Science Pool

Rising antimicrobial resistance challenges our ability to combat bacterial infections. The problem is acute for tuberculosis (TB), the leading cause of death from infection before COVID-19.

Here, we developed a framework for multiple pharmaceutical companies to share proprietary information and compounds with multiple laboratories in the academic and government sectors for a broad examination of the ability of β-lactams to kill Mycobacterium tuberculosis (Mtb). In the TB Drug Accelerator (TBDA), a consortium organized by the Bill & Melinda Gates Foundation, individual pharmaceutical companies collaborate with academic screening laboratories.

• In this paper we describe strategies used to prioritize thousands of β-lactams from multiple companies into a small test set for further characterization.
• In a striking contrast to historical expectation, 18% of β-lactams screened were active against Mtb, many without a β-lactamase inhibitor.
• One potent cephaloporin was active in Mtb-infected mice.

GET THE PAPER

The 12^th edition of our Drug Discovery Update (DDup) provides insights into exciting new developments in 3D cell models including microtissues, organoids and organ-on-a-chip technology.

In this edition, it covers:

• an introduction to 3D cellular models
  • the need for better models to improve translation from in vitro to in vivo
  • the relevance of 3D cellular models to kidney disease modelling and drug induced toxicity prediction
• an overview of Evotec's 3D in vitro platforms
  • glomerulus-on-a-chip to study kidney disease
  • kidney organoids to study polycystic kidney disease
  • organ microtissues to predict drug-induced toxicity
• interviews with experts Dr Christodoulos Xinaris, Dr Reiner Class, Dr Magali Ferro and Dr Stephanie Ryder

LEARN MORE

Huntington´s Disease (HD) is a hereditary neurodegenerative disorder that is caused by a mutation in the huntingtin gene (mHTT) leading to deposition of pathologic protein aggregates in the brain.

This paper focuses on:

• Visualization of mHTT aggregate expression by positron emission tomography (PET) in rodent HD model
• Utility of the previously described novel PET imaging ligand CHDI-180 for detection of mHTT in rodent and post-mortem human HD brain
• Ability of CHDI-180 to serve as functional response indicator for mHTT lowering therapies

GET THE PAPER

Date: 13 - 14 April 2022

Location: Hyatt Regency San Francisco Airport, San Francisco, CA, United States

Who's Attending? 

• John Gunther, Senior Director Business Development at Just - Evotec Biologics

Presentation
Advanced Continuous Manufacturing Solutions to Accelerate Time to Clinic and Secure Cost-Effective Commercial Supply

• The talk will be given by Magnus Schroeder, VP Process and Product Design at Just - Evotec Biologics
  
  

If you wish to meet with us in San Francisco, get in touch via the form below, we will be happy to arrange a meeting. We hope to see you there!

With more then 15 years of screening experience in anti-infectives, including antibacterials and antivirals, Evotec's medium throughput and high throughput screening expertise extends to BSL2⁺ and BSL3 containment level. 

DOWNLOAD NOW